Drug intelligence / Profile preview

BIIL 284 BS + theophylline

Development stage: Discontinued
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

BIIL 284 BS + theophylline is a combination therapy consisting of BIIL 284 BS, a leukotriene B4 (LTB4) receptor antagonist, and theophylline, a methylxanthine bronchodilator. BIIL 284 BS acts by inhibiting the LTB4 receptor, which is involved in mediating airway inflammation, particularly in cystic fibrosis. Theophylline works by inhibiting phosphodiesterase, leading to bronchodilation and reduced airway obstruction. The combination was explored for the treatment of lung disease, primarily cystic fibrosis, aiming to target inflammation and offer symptomatic relief[2].

Other names: BIIL 284 BS + theophylline

Targets

LTB4R (Leukotriene B4 Receptor 1)

Beyond the preview

Go deeper on BIIL 284 BS + theophylline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIIL 284 BS + theophylline.

Explore the full profile